UCSF Clinical Trials Update

he following information is provided by UCSF, an ANCO Institutional Member.

We would like to call your attention to the following two new clinical trials for peripheral T-cell Lymphoma and CLL at UCSF:

First-line Treatment of Peripheral T-cell Lymphoma
This multi-center trial uses the combination of gemcitabine/vinorelbine/doxil and augmented CHOP / high-dose methotrexate as induction therapy followed by stem cell mobilization/consolidation with high-dose cytarabine, etoposide and denileukin diftitox (Ontak) as in vivo purge. This is followed by high-dose chemotherapy and auto-transplant. A short course of post-transplant maintenance Ontak is then administered. Most patients with untreated alk-1-negative peripheral T-cell lymphomas are eligible.

Phase II study of Flavoperidol for refractory CLL
Requires brief hospital stay in ICU for prevention and monitoring of tumor lysis syndrome. This is a highly active drug and one of the few agents active in patients with 17p deletions. Most patients with relapsed / refractory CLL who have received one or more prior therapies will be eligible. Patients must have received prior alkylating agents and be fludarabine refractory.
If you have a patient who might be helped by one of these protocols, please call:

Lawry Kaplan, MD
415-443-9188 (pager)
415-353-2661 (office VM)

or

Beth Davis, Research Office Manager
415-502-3176